Pharmaceutical Co-Crystals

Crystal engineering has evolved in such a manner that it is now synonymous with the paradigm of supramolecular synthesis, that is, it invokes self-assembly of existing molecules to generate a wide range of new solid forms without the need to break or form covalent bonds. This review addresses how cr...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical sciences 2006-03, Vol.95 (3), p.499-516
Main Authors: Vishweshwar, Peddy, McMahon, Jennifer A., Bis, Joanna A., Zaworotko, Michael J.
Format: Article
Language:English
Subjects:
Biological and medical sciences
Carbamazepine - chemistry
Chemistry, Pharmaceutical
crystal engineering
Crystallization
General pharmacology
hydrogen bond
Medical sciences
pharmaceutical co-crystal
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Piracetam - chemistry
polymorphism
supramolecular synthesis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Crystal engineering has evolved in such a manner that it is now synonymous with the paradigm of supramolecular synthesis, that is, it invokes self-assembly of existing molecules to generate a wide range of new solid forms without the need to break or form covalent bonds. This review addresses how crystal engineering has been applied to active pharmaceutical ingredients, API's, with emphasis upon how pharmaceutical co-crystals, a long known but little explored alternative to the four traditionally known forms of API, can be generated in a rational fashion. Case studies on Carbamazepine (CBZ) and Piracetam are presented which illustrate the relative ease with which pharmaceutical co-crystals can be prepared and their diversity in terms of composition and physical properties. © 2006 Wiley-Liss, Inc. and the American Pharmacists Association.
ISSN:0022-3549
1520-6017
DOI:10.1002/jps.20578